The approval marks a turning point for a malignancy that has frustrated oncologists for decades. Pancreatic cancer kills roughly 50,000 Americans each year and has one of the lowest five-year survival rates of any major cancer, largely because most cases are diagnosed late and tumors resist conventional treatment.
A First-in-Class Attack on a Genetic Cause
Rasonque, whose generic name is daraxonrasib, was developed by Redwood City–based Revolution Medicines. It is the first approved therapy to go after a genetic mutation that directly fuels pancreatic tumor growth, rather than broadly poisoning dividing cells the way traditional chemotherapy does.
Until now, oncologists treating advanced pancreatic cancer had little to offer beyond chemotherapy regimens that marginally extended life. The disease’s dense stroma, late presentation, and limited actionable mutations have made it one of the hardest targets in oncology drug development.
Trial Results That Changed Practice
The FDA’s decision rests on a clinical trial that read out earlier this year and was described by investigators as practice-changing. Patients with advanced pancreatic cancer received Rasonque as a second-line treatment, after their disease had progressed following initial therapy.
Those given Rasonque survived a median of 13.2 months, compared with 6.7 months for patients who received standard chemotherapy in the control arm. The near-doubling of median overall survival is rare in pancreatic cancer trials, where incremental gains of weeks have historically been the norm.
Andrew Ko, a medical oncologist specializing in gastrointestinal cancers, called the approval a watershed moment. “It will be transformative in the way we treat pancreas cancer,” Ko said. “It’s the biggest development we’ve had in pancreas cancer in decades.”
Why Genetic Targeting Matters
Most approved cancer drugs in recent years have succeeded by homing in on specific molecular features of tumors — a strategy that has transformed outcomes in lung, breast, and melanoma patients. Pancreatic cancer has lagged behind, partly because fewer patients carry mutations that are druggable with existing technology.
Rasonque breaks that pattern by addressing one of the genetic drivers long implicated in pancreatic tumors. By blocking the signaling pathway that lets mutant cells proliferate, the drug aims to choke off tumor growth at its source rather than relying on the blunt damage of chemotherapy.
Oncologists expect the approval to trigger broader genetic testing of pancreatic cancer patients at diagnosis. Identifying who carries the relevant mutation will determine who can benefit, and earlier molecular profiling could shift Rasonque into first-line use in future trials.
What Happens Next
Rasonque’s commercial launch and insurance uptake will determine how quickly patients can access it. Revolution Medicines will need to price the therapy in a way that payers accept, given that pancreatic cancer patients are often older and covered by Medicare.
Researchers are already planning combination studies — pairing Rasonque with immunotherapy or other targeted agents — to see whether survival can be pushed further. Trials testing the drug as a first-line treatment, before chemotherapy, are likely to follow.
For now, the approval gives oncologists a meaningful second option for a disease that has had almost none. After decades of incremental progress, Rasonque represents the first evidence that genetic targeting can meaningfully extend lives in pancreatic cancer.
— Aisha Mensah, health desk, AXO News